tert-butyl (2-(2-(2-(methylamino)ethoxy)ethoxy)ethyl)carbamate | 880359-74-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (2-(2-(2-(methylamino)ethoxy)ethoxy)ethyl)carbamate
• 英文别名: tert-butyl N-[2-[2-[2-(methylamino)ethoxy]ethoxy]ethyl]carbamate；BocNH-PEG2-CH2CH2NHMe
• CAS: 880359-74-0
• 化学式: C₁₂H₂₆N₂O₄
• 分子量: 262.349
• InChiKey: FLNJYYUCKRLBCJ-UHFFFAOYSA-N

物化性质

• 沸点：
  361.5±27.0 °C(Predicted)
• 密度：
  1.007±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  18
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  68.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl (2-(2-(2-(methylamino)ethoxy)ethoxy)ethyl)carbamate 在 potassium carbonate 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 0.25h， 生成 (2-(((2-(2-(2-aminoethoxy)ethoxy)ethyl)(methyl)amino)methyl)phenyl)boronic acid
  参考文献：
  名称：

  Chemiluminescent acridinium-9-carboxamide boronic acid probes: Application to a homogeneous glycated hemoglobin assay

  摘要：

  Chemiluminescent acridinium-9-carboxamide probes containing 1, 3, 9, and 27 phenylboronic acids were prepared and their chemiluminescent properties evaluated. The relative chemiluminescent signal from the probes varied from 4 to 0.83 x 10(19) counts/mol across the series, while the apparent affinity of the probes for the diabetes marker glycated hemoglobin increased from 211 to 0.43 mu M. The dose-dependent modulation of the chemiluminescent intensity of the probes upon binding was used to demonstrate a homogeneous assay for glycated hemoglobin. (C) 2006 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2005.11.062
• 作为产物：
  描述：

  2-[2-(2-氨乙氧基)乙氧基]乙醇 在 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 tert-butyl (2-(2-(2-(methylamino)ethoxy)ethoxy)ethyl)carbamate
  参考文献：
  名称：

  IRAK DEGRADERS AND USES THEREOF

  摘要：

  本发明提供了化合物、其组合物以及使用这些化合物的方法。

  公开号：

  US20190192668A1

文献信息

• [EN] SELF-IMMOLATIVE LINKERS CONTAINING MANDELIC ACID DERIVATIVES, DRUG-LIGAND CONJUGATES FOR TARGETED THERAPIES AND USES THEREOF<br/>[FR] LIEURS AUTO-IMMOLABLES CONTENANT DES DÉRIVÉS D'ACIDE MANDÉLIQUE, CONJUGUÉS MÉDICAMENT-LIGAND POUR THÉRAPIES CIBLÉES, ET LEURS UTILISATIONS
  申请人：ASANA BIOSCIENCES LLC

  公开号：WO2015038426A1

  公开（公告）日：2015-03-19

  The invention provides a therapeutic drug and targeting conjugate, pharmaceutical compositions containing these conjugates in pharmaceutical composition, and uses of these conjugates in anti-neoplastic and other therapeutic regimens. Also provided are novel intermediates thereof. The conjugates provide a therapeutic drug fragment or prodrug fragment bound to a targeting moiety via a linker which comprises a substrate cleavable by a protease such as Cathepsin B. The targeting moiety is a ligand which targets a cell surface molecule, such as a cell surface receptor on an anti-neoplastic cell. The ligand may function solely as a targeting moiety or may itself have a therapeutic effect. Following administration of the therapeutic drug and targeting conjugate of formula I and exposure of the conjugate to the protease specific for the substrate, the linker is cleaved and the targeting moiety is separated from the conjugate, which causes the drug fragment or prodrug fragment to convert to the drug or prodrug. The recited conjugates are useful in anti-neoplastic therapies. Also provided are methods of making the therapeutic drug and targeting conjugates and intermediates thereof, and kits comprising the therapeutic drug and targeting conjugates.

  该发明提供了一种治疗药物和靶向共轭物，包含这些共轭物的药物组合物，以及这些共轭物在抗肿瘤和其他治疗方案中的用途。还提供了其新颖的中间体。这些共轭物通过一个由蛋白酶如半胱氨酸蛋白酶B可切割的底物组成的连接物将治疗药物片段或前药片段与靶向基团结合。靶向基团是一个以细胞表面分子为靶点的配体，例如抗肿瘤细胞上的细胞表面受体。该配体可能仅作为靶向基团，也可能本身具有治疗效果。在给药公式I的治疗药物和靶向共轭物并使共轭物暴露于特异于底物的蛋白酶的情况下，连接物被切割，靶向基团与共轭物分离，导致药物片段或前药片段转化为药物或前药。所述的共轭物在抗肿瘤疗法中很有用。还提供了制备治疗药物和靶向共轭物及其中间体的方法，以及包含治疗药物和靶向共轭物的试剂盒。
• [EN] METHODS AND COMPOUNDS FOR TREATING DISORDERS<br/>[FR] PROCÉDÉS ET COMPOSÉS POUR TRAITER DES TROUBLES
  申请人：FOGHORN THERAPEUTICS INC

  公开号：WO2019152440A1

  公开（公告）日：2019-08-08

  The present invention relates to methods and compositions for the treatment of BAF-related disorders such as cancers and viral infections.

  本发明涉及用于治疗与BAF相关的疾病，如癌症和病毒感染的方法和组合物。
• [EN] COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS<br/>[FR] COMPOSÉS ET PROCÉDÉS D'INHIBITION D'UN ANTIPORT À MÉDIATION PAR NHE DANS LE TRAITEMENT DE TROUBLES ASSOCIÉS À UNE RÉTENTION DE FLUIDE OU À UNE SURCHARGE DE SEL ET DE TROUBLES DU TRACTUS GASTRO-INTESTINAL
  申请人：ARDELYX INC

  公开号：WO2014029983A1

  公开（公告）日：2014-02-27

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

  本公开涉及化合物和治疗液体潴留或盐过多相关疾病的方法，例如心力衰竭（特别是充血性心力衰竭）、慢性肾脏疾病、晚期肾脏疾病、肝脏疾病和过氧化物酶体增殖物激活受体（PPAR）γ激动剂诱导的液体潴留。本公开还涉及化合物和治疗高血压的方法。本公开还涉及化合物和治疗胃肠道疾病的方法，包括治疗或减轻与胃肠道疾病相关的疼痛。
• One‐Step Synthesis of Photoaffinity Probes for Live‐Cell MS‐Based Proteomics
  作者：David J. Fallon、Stephanie Lehmann、Chun‐wa Chung、Alex Phillipou、Christian Eberl、Ken G. M. Fantom、Francesca Zappacosta、Vipulkumar K. Patel、Marcus Bantscheff、Christopher J. Schofield、Nicholas C. O. Tomkinson、Jacob T. Bush

  DOI：10.1002/chem.202102036

  日期：2021.12.20

  Get PALs quick: A multicomponent reaction for the one-step synthesis of PAL probes. A library of diverse bromodomain (BET)-targeting PAL probes was synthesized and profiled extensively (physicochemical properties, biochemical and cellular activities, photolabeling efficiencies and crystallographic studies). Optimal probes were profiled by MS-based proteomics to capture BET proteins from live cells

  快速获取 PAL ：一种用于一步合成 PAL 探针的多组分反应。合成了多种靶向溴结构域 (BET) 的 PAL 探针库，并对其进行了广泛的分析（物理化学性质、生化和细胞活性、光标记效率和晶体学研究）。通过基于 MS 的蛋白质组学对最佳探针进行分析，以从活细胞中捕获 BET 蛋白，并揭示其潜在的靶向/脱靶特征。我们设想这种方法可用于快速访问其他感兴趣化合物的 PAL 探针并获得其目标概况。
• [EN] METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1<br/>[FR] PROCÉDÉS ET COMPOSÉS POUR MODULER UNE DYSTROPHIE MYOTONIQUE DE TYPE 1
  申请人：DESIGN THERAPEUTICS INC

  公开号：WO2022126000A1

  公开（公告）日：2022-06-16

  The present disclosure relates to transcription modulator molecule compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The transcription modulator comprising a) the first terminus comprising a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) a second terminus comprising a protein-binding moiety capable of binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) an oligomeric backbone comprising a linker between the first terminus and the second terminus.

  本公开涉及转录调节分子化合物和调节dmpk表达的方法，以及治疗dmpk发挥积极作用的疾病和病症的方法。所述转录调节剂包括a）第一端包括DNA结合基团，能够非共价地结合到核苷酸重复序列CAG或CTG上；b）第二端包括蛋白结合基团，能够结合到调节分子上，该调节分子调节包括核苷酸重复序列CAG或CTG的基因的表达；以及c）寡聚骨架，包括连接第一端和第二端的连接物。